We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
OPKO Health's (OPK) BioReference Extends Digital Health Access
Read MoreHide Full Article
OPKO Health Inc.’s (OPK - Free Report) BioReference Laboratories, Inc. unveils Scarlet Health — an in-home, fully-integrated digital platform — that ensures access to on-demand diagnostic services.
The launch is likely to provide a boost to the company’s Diagnostics segment.
Scarlet Health at a Glance
Scarlet Health is a fully-integrated digital platform proving healthcare services to patients at the comfort of their homes. The platform has been designed to provide convenient, secure and safe healthcare services.
Scarlet Healthcare redefines healthcare by creating digitally enabled consumer-centric approach and provide access to wide array of tests — from COVID-19 to chronic conditions.
Significance of the Launch
Scarlet Healthcare provides an innovative and flexible alternative to conventional patient service centres for collection of test specimen.
The new technology enables healthcare providers to secure vital diagnostic information about patients consistently and easily for faster diagnosis. Patients will obtain real-time updates and relevant information, as how to plan for the visit or track the arrival of healthcare professionals.
The new technology improves and accelerates patient-centered health care, utilizing similar on-demand services that patients can use from the comfort of their homes. With this innovation, BioReference can revolutionize delivery of healthcare services by bridging the gap between telemedicine and traditional health care.
Industry Prospects
Per a report by Global Market Insights, global digital health market was worth $106 billion in 2019 and is anticipated to reach $634.9 billion by 2026 at a CAGR of 28.5%. Increasing number of smartphone users across the globe is driving market growth. Furthermore, rise in COVID-19 cases across the globe has increased the adoption of digital health technologies and will boost the digital health industry growth.
Notable Developments
In October 2020, OPKO Health’s BioReference Laboratories introduced COVID-19 molecular testing program for New York City schools throughout 2020-2021 school year to ensure a safer environment. Additionally, BioReference is collecting specimens from principals, teachers, administration and students from more than 950 schools across New York City.
In the same month, BioReference Laboratories announced that it has started accepting specimens for a new multiplex COVID-19 and influenza test, which can be utilized by healthcare providers, clinics and health systems across the United States. This test will help in the diagnosis of COVID-19 and Influenza A or B (flu). This test enables healthcare providers for rapid diagnosis and offer surveillance for flu and COVID-19, while conserving critical testing samples.
Price Performance
Share of the company have surged 196% in a year’s time compared with industry’s growth of 25%.
Zacks Rank and Key Picks
Currently, OPKO Health carries a Zacks Rank # 3 (Hold).
Some better-ranked stocks from the medical space include Cantel Medical Corp. , Hologic, Inc. (HOLX - Free Report) , Alphatec Holdings, Inc. (ATEC - Free Report) . While Cantel Medical and Hologic sport a Zacks Rank# 1 (Strong Buy), Alphatec carries a Zacks Rank # 2 (Buy). You can see the complete list of Zacks #1 Rank stocks here.
Cantel Medical has a projected long-term earnings growth rate of 19%
Hologic has a projected long-term earnings growth rate of 17.4%
Alphatec has an estimated long-term earnings growth rate of 39.1%
Legal Marijuana: An Investor’s Dream
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.
Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Image: Bigstock
OPKO Health's (OPK) BioReference Extends Digital Health Access
OPKO Health Inc.’s (OPK - Free Report) BioReference Laboratories, Inc. unveils Scarlet Health — an in-home, fully-integrated digital platform — that ensures access to on-demand diagnostic services.
The launch is likely to provide a boost to the company’s Diagnostics segment.
Scarlet Health at a Glance
Scarlet Health is a fully-integrated digital platform proving healthcare services to patients at the comfort of their homes. The platform has been designed to provide convenient, secure and safe healthcare services.
Scarlet Healthcare redefines healthcare by creating digitally enabled consumer-centric approach and provide access to wide array of tests — from COVID-19 to chronic conditions.
Significance of the Launch
Scarlet Healthcare provides an innovative and flexible alternative to conventional patient service centres for collection of test specimen.
The new technology enables healthcare providers to secure vital diagnostic information about patients consistently and easily for faster diagnosis. Patients will obtain real-time updates and relevant information, as how to plan for the visit or track the arrival of healthcare professionals.
The new technology improves and accelerates patient-centered health care, utilizing similar on-demand services that patients can use from the comfort of their homes. With this innovation, BioReference can revolutionize delivery of healthcare services by bridging the gap between telemedicine and traditional health care.
Industry Prospects
Per a report by Global Market Insights, global digital health market was worth $106 billion in 2019 and is anticipated to reach $634.9 billion by 2026 at a CAGR of 28.5%. Increasing number of smartphone users across the globe is driving market growth. Furthermore, rise in COVID-19 cases across the globe has increased the adoption of digital health technologies and will boost the digital health industry growth.
Notable Developments
In October 2020, OPKO Health’s BioReference Laboratories introduced COVID-19 molecular testing program for New York City schools throughout 2020-2021 school year to ensure a safer environment. Additionally, BioReference is collecting specimens from principals, teachers, administration and students from more than 950 schools across New York City.
In the same month, BioReference Laboratories announced that it has started accepting specimens for a new multiplex COVID-19 and influenza test, which can be utilized by healthcare providers, clinics and health systems across the United States. This test will help in the diagnosis of COVID-19 and Influenza A or B (flu). This test enables healthcare providers for rapid diagnosis and offer surveillance for flu and COVID-19, while conserving critical testing samples.
Price Performance
Share of the company have surged 196% in a year’s time compared with industry’s growth of 25%.
Zacks Rank and Key Picks
Currently, OPKO Health carries a Zacks Rank # 3 (Hold).
Some better-ranked stocks from the medical space include Cantel Medical Corp. , Hologic, Inc. (HOLX - Free Report) , Alphatec Holdings, Inc. (ATEC - Free Report) . While Cantel Medical and Hologic sport a Zacks Rank# 1 (Strong Buy), Alphatec carries a Zacks Rank # 2 (Buy). You can see the complete list of Zacks #1 Rank stocks here.
Cantel Medical has a projected long-term earnings growth rate of 19%
Hologic has a projected long-term earnings growth rate of 17.4%
Alphatec has an estimated long-term earnings growth rate of 39.1%
Legal Marijuana: An Investor’s Dream
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.
Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Download Marijuana Moneymakers FREE >>